The 72 kDa IE1 protein of human cytomegalovirus (HCMV) is one of a few viral regulatory proteins expressed immediately after infection of a host cell. Although it is now well-established that IE1 is a potent transcriptional activator of the human immunodeficiency virus (HIV) long terminal repeat (LTR), the identity of the nucleotide sequence responsive to IE1 remains elusive and the molecular mechanism of this interaction is not well-understood. We have constructed various LTR mutants and tested them for their ability to be activated by IE1 using transient transfection assays. Mutations in the NFqcB sites, of either a few changes in the nucleotide sequence or a deletion of the entire region, abrogated IEl-driven transactivation. Deletion of the Tat-responsive element (TAR) had no significant effect on reporter expression. Mutations in the Spl sites or the TATA box significantly lowered LTR activity, but this is probably due to an effect on the general transcription system, as these elements are also required for the transactivation of the LTR by many stimulators including Tat, tumour necrosis factor alpha (TNF-cQ, E1A/E1B and phorbol myristate acetate (PMA). In addition, gel retardation analysis demonstrated that NF-KB activity was significantly increased in human T lymphoid H9 and monocytic U937 cell lines constitutively expressing IE1. Taken together, these data suggest that NF-tcB plays a central role in the IE1 transactivation of the HIV LTR.
Introduction
Much attention has been focused on the possibility that viral cofactors may play an important role in the activation of human immunodeficiency virus (HIV) gene expression. Among candidate viruses, the herpesviruses have often been mentioned because they are prevalent in certain high risk populations and cause increased morbidity and mortality in individuals with AIDS (Barry et al., 1990; Biegalke & Geballe, 1991 ; Davis et al., 1987; Fiala et al., 1986; Gendelman et al., 1986; Ghazal et al., 1991 ; Gimble et al., 1988 ; Macher et al., 1983 ; Mallon et al., 1990; Markovitz et al., 1989; Mosca et al., 1987; Ostrove et al., 1987; Rando et al., 1987 Rando et al., , 1990 . It has been postulated that HIV in vivo may be activated by such viruses, accelerating viral replication and subsequently hastening the onset of AIDS (Nelson et aI., 1990) . In support of this hypothesis, it has been reported that the gene products of several DNA viruses can efficiently transactivate the HIV promoter (Barry et al., 1990; Biegalke & Geballe, 1991; Davis et al., 1987; Ensoli et al., 1989; Ghazal et al., 1991 ; Hagemeier et al., * Author for correspondence. Fax + 82 2 875 0907. e-mail sunyoung@power 1 .snu.ac.kr 1992; Mallon et al., 1990; Rando et al., 1987) , and that HIV replication can be increased by the presence of other viruses in cell culture systems (Albrecht et al., 1989; Casareale et al., 1989; Ho et al., 1990; Lusso et al., 1989; Skolnik et al., 1988) .
Human cytomegalovirus (HCMV) has been studied extensively as a possible viral cofactor in the progression of HIV infection to AIDS. HCMV is widespread in individuals infected with HIV, and has been associated with an accelerated course of disease progression (Fiala et al., 1986; Macher et al., 1983; Webster et al., 1989) . It has also been reported that HCMV and HIV can infect the same tissues or cells in patients with AIDS (Belec et al., 1990; Finkle et al., 1991 ; Nelson et al., 1988) and that coinfection of cell lines by the two viruses increases HIV replication (Casareale et al., 1989; Ho et al., 1990; Skolnik et at., 1988) . Studies of the involvement of HCMV in the activation of HIV have largely focused on the two immediate-early gene products of HCMV, IE1 and IE2. It is generally agreed that these proteins can efficiently transactivate the HIV long terminal repeat (LTR) (Barry et al., 1990; Biegalke & Geballe, 1991; Ghazal et al., 1991; Hagemeier et al., 1992; Minton et al., 1994; Walker et al., 1992) , although there are exceptions (Davis et al., 1987; Rando et al., 1990) . However, identification of the nucleotide sequences 0001-3455 © 1996 SGM responsive to IE1 and the molecular mechanism of this transactivation varies between different laboratories. For example, Walker et al. (1992) reported that the region between nucleotides -46 and -37, in addition to the TATA box, is absolutely required. In contrast, Hagemeier et al. (1992) found that IEl-driven transactivation of the LTR is independent of the TATA box. Biegalke & Geballe (1991) performed a comprehensive analysis on the transactivation of the HIV LTR by IE1 and IE2. Although the effect of IE1 alone was not extensively studied, it is clear that sequence 3' from nucleotide -19 is dispensable for IE1 responsiveness. In addition, there are also at least two reports claiming that IE1 does not transactivate the LTR (Davis et al., 1987; Rando et al., 1990 ).
Other researchers have investigated possible synergistic effects of IE1 and IE2 on transactivation of the LTR, but discrepancies are also evident in their work. There are some reports that the nucleotide sequences from -6 and + 20 are critical for transactivation by the IE gene products (Barry et al., 1990) , whereas others found that the region between -174 and -163 was essential for synergistic activation (Ghazal et al., 1991) . At present, it is difficult to comprehend why there are so many discrepancies. Possibly, this is due to the use of different cell lines, as virtually every report on IE1 transactivation of the HIV LTR has used a different cell line. It is worth noting that a human T cell line was used in only one study (Ghazal et al., 1991) , with most investigators using cells of fibroblast or epithelial origin such as HF, MRC-5, Vero, IBR, HeLa and rhabdomyosarcoma (Barry et al., 1990; Biegalke & Geballe, 1991; Davis et al., 1987; Hagemeier et al., 1992; Markovitz et al., 1989; Rando et al., 1990; Walker et al., 1992) . It is also possible that the various plasmids used in these studies were significantly different. Many groups used an expression vector expressing IE1 and IE2 simultaneously, making it difficult to determine the nucleotide sequence that is specifically responsive to an individual factor. Furthermore, the actual production of these proteins from the expression vectors used was not confirmed in most reports.
Our work was designed to more clearly define the region of the HIV LTR that is responsive to IE1, and thus to understand the molecular mechanism of its transactivation. We have recently found that IE1 specifically activates the cellular transcription factor NF-KB. This observation led us to re-evaluate the mechanism of IE1 transactivation of the HIV LTR. For our study, we constructed an expression vector that produced only the 72 kDa IE1 protein. We used human T lymphoid and monocytic lines as host cells, because they represent the major target cell types for HIV infection and may therefore have more relevance to a possible in vivo interaction between HCMV and HIV. In addition, it has been shown that the 72 kDa IE1 protein is expressed upon HCMV infection of lymphocytes, although its growth is restricted (Einhorn & Ost, 1984; Nowlin et al., 1991; Rice et al., 1984; Schrier et al., 1985) . We also constructed human T lymphoid and monocytic lines constitutively expressing IE1 in order to minimize artefacts that can arise from the use of transient transfection systems. Using these cell lines, we demonstrated that NF-~cB is a key player in the transactivation of the HIV LTR by IE1.
Methods
Cells. U937 human promouocytic cells (ATCC CRL 1593) and HeLa human cervical epitheloid carcinoma (ATCC CCL2) were obtained from the American Type Culture Collection. The H9 human T cell lymphoid line is a subclone derived from HUT78, and was obtained from the NIH AIDS Research and Reference Reagent Program. The human embryonic kidney line 293T was provided by Stephen Smale (University of Californi~Los Angeles, USA). U937 and H9 cells were grown in RPMI 1640, and 293T and HeLa cells were grown in Dulbecco's modified Eagle's medium. Each medium was supplemented with 10% fetal bovine serum, 120pg/ml penicillin-G (Sigma; 1690 U/mg) and 200 gg/ml streptomycin (Sigma; 750 U/mg).
Plasmids and construction of L TR mutants. Plasmids 938, A339, A 167 (p-167), All8 (-448/-118), 943-2 (-448/-58), 943-1 (-448/-40), 946 (-448/-339), 978 (ATAR) and 952 (KB-ATAR) were described previously (Kiln et al., 1990; Lee et al., 1992; Sakaguchi et al., 1991) . Plasmid names in parentheses are indicated as described by Lee et al. (1992) . AKB is the plasmid p942 described by Nabel & Baltimore (1987) and Sakaguchi et al. (1991) . Plasmids J16 and J32 (Pierce et al., 1988) were provided by Jackie Pierce (Brandes University, Waltham, Mass., USA). Plasmids ASpl and ATATA, in which the respective transcriptional elements were replaced with XbaI and XhoI linkers respectively, were constructed by amplifying two fragments from the LTR region by PCR and subsequently joining them. Oligonucleotide primers were designed so that the Spl sites or TATA box were selectively deleted as shown in Fig. 5 . Detailed procedure and supplementary data regarding the construction of these plasmids is available upon request, pEQ326 and pEQ273 are the plasmids containing the immediate-early region of HCMV (Biegalke & Geballe, 1991) , and were provided by Adam Geballe (Fred-Hutchinson Cancer Center, Seattle, USA).
Metabolic labelling and radioimmunoprecipitation. The procedure for metabolic labelling and radioimmunoprecipitation was as described previously (Beg et al., 1993) except that 100 pCi each of [asS]methionine and [35S]cysteine were used.
TransJection and CAT assays. U937 ceils were transfected with 1 Ixg of various LTR-CAT fusion constructs, along with 2 jag of the expression vector pRSV-IEI or the control plasmid pRc/RSV, using DEAE-dextran (Grosschedl & Baltimore, 1985) . For the CAT assay, 90 gg protein was incubated with [laC]chloramphenicol for 45 min at 37 °C. Acetylated products were fractionated by thin-layer chromatography, visualized by autoradiography, and excised from the plate for radioactivity determination in a scintillation counter.
Gel retardation assays. Nuclear extracts were prepared and analysed by electrophoretic mobility shift assay (EMSA) as described previously (Dignam et al., 1983) . Ten micrograms of nuclear extracts were incubated with 32P-labelled NF-KB oligonucleotide 
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The reaction mixture contained 3 lag poly(d~dC), 0.2 ng of radioactive oligonucleotide and nuclear extracts in binding buffer (10mM-Tris-HCl, pH 7"5, 50 mM-NaC1, 1 mM-DTT, 5 % glycerol, 20 lag bovine serum albumin, 3 mM-GTP) in 20 lal total volume. After incubation for 20 min, at room temperature, the reactions were analysed on a lowionic strength 4 % polyacrylamide gel. The specificity of the retarded complexes were confirmed by competition with 100-fold excess of cold wild-type, or mutant oligonucleotide **ge
To test whether the electrophoretically retarded DNA protein complex indeed contained NF-KB, nuclear extracts were incubated at room temperature for 15 min with defined antibodies (specific for IE1 or the p50 subunit of NF4rB, and pre-immune sera) prior to the addition of labelled NF-KB oligonucleotide. Antibody to p50 was purchased from Santa Cruz Biochemicals (Catalogue number SC-114X).
Results

Construction of an IE1 expression vector
Because the immediate-early region of HCMV generates a variety of mRNAs and protein species, it was important to construct an expression vector that specifically encoded only the IE1 protein. The entire coding sequence of IE1, from exon 1 to exon 4, was isolated from pEQ326 by partial SacI digestion, and placed under the control of the Rous sarcoma virus (RSV) LTR in plasmid Rc/RSV (Invitrogen) to produce the plasmid RSV-IE1. [Plasmid pEQ326 contains the entire ttCMV immediate-early gene including the promoter and five exons (Biegalke & Geballe, 1991) .] Exon 4, which is specific to IE1, was cloned by PCR, fused to the maltose binding protein (MBP), and expressed in Escherichia colt (Fig. 1 a) . Rabbits were immunized with the purified fusion protein, and antisera that specifically recognizes IE1 but not IE2 was produced (data not shown). The 293T human embryonic kidney cells were transfected with defined expression vectors, metabolically labelled with [a~S]cysteine and [aSS]methionine, and then immunoprecipitated with this antiserum. When cells were transfected with RSV-IE1 and immunoprecipitated with pre-immune serum, no protein band was detected ( Fig.  1 b, lane 1) . As a positive control, cells were transfected with plasmid pEQ273, which expresses IE1, but not IE2, because it lacks the exon 5 (Biegalke & Geballe, 1991) . 
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87 Transfected cells expressed a protein b a n d of approximately 72 k D a (Fig. 1 b, lane 4) . W h e n cell lysates from transfectants of RSV-IE1 were i m m u n o p r e c i p i t a t e d with the specific antiserum, an IE1 protein of a p p r o x i m a t e l y 72 k D a was readily detectable (Fig. 1 b, lane 3) . As a further control, cells were transfected with a control expression vector (RSV-EI) containing the IE1 coding sequence in an antisense orientation. The IEl-specific antiserum did not detect any b a n d (Fig. lb, lane 2) . These results confirmed that RSV-IE1 indeed p r o d u c e d the IE1 protein.
Deletion analysis of the H I V L T R
To test whether IE1 transactivated the H I V L T R , an H I V L T R -C A T fusion construct was transfected into the h u m a n monocytic cell line U937 in the presence or absence of the IE1 expression vector, RSV-IE1. Transfection of the L T R -C A T construct containing a fulllength p r o m o t e r resulted in undetectable levels of C A T activity (Fig. 2, lane 1) . As expected, cotransfection with RSV-IE1 resulted in a large increase in C A T activity (Fig. 2, lane 2) . Similar results were obtained for most of the cell lines we tested, including H9, 293T, Vero and H e L a cells (data not shown).
In order to localize the D N A sequence element responsive to IE1, we used a series o f deletion constructs o f the H I V L T R and for each we tested the ability to be induced by IE1. Deletion of nucleotide sequences u p s t r e a m from the NF-•B sites did not significantly affect the extent of transactivation by IE1 (Fig. 2, lanes  3-6) . However, deletion of the NF-KB sites significantly lowered L T R activity relative to the wild-type plasmid (Fig. 2, lanes 7 and 8) . F u r t h e r deletion of the L T R resulted in undetectable levels of C A T activity. This labelled NF-tcB oligonucleotide. Nuclear extracts from U937 or H9 cells expressing IE1 (IE1) or just containing the control vector (C) were incubated with labelled probe whose sequence was taken from the KB sites of the HIV-I LTR (--99 to --76). NF-tcB-specific DNA protein complexes were verified by competition assay which involved incubating the protein sample from lanes 2 or 6 with unlabelled wild-type (W) or mutated (M) oligonucleotide (lanes 3, 4, 7 and 8). S, specific DNA protein complex; FP, flee probe. (c) Binding inhibition assay. To test that the electrophoretically retarded DNA-protein complex indeed contained NF-KB, nuclear extracts from H9 cells expressing IE1 were incubated with antibodies specific for the p50 subunit of NF4cB or IEI (lanes 2 and 4), and pre-immune sera (PI) (lane 3). In lane 1 (C), nuclear extracts were not treated with any antibody.
analysis suggested that deletion of the NF-KB sites alone could abrogate IEl-driven transactivation of the HIV LTR.
NF-KB is essential for IE1 transactivation of the LTR
To confirm the role of NF-KB in IEl-driven transactivation, we transfected a further series of LTR constructs containing mutated KB sites and analysed the effect of IE1 transactivation. The full-length LTR was efficiently transactivated by IE1 (Fig. 3, lanes 1 and 2) . The same construct harbouring point mutations in the tcB sites did not produce any detectable levels of CAT activity (Fig. 3, lanes 3 and 4) . For a further confirmation, we also tested two mutant LTR constructs in which the Tat-responsive element (TAR) was deleted, containing either wild-type or mutated KB sites. Despite the deletion of the TAR sequence, the LTR containing wild-type ~¢B sites was efficiently transactivated by IE1 (Fig. 3, lanes 5 and 6) . The magnitude of this transactivation was always similar to that of the wildtype LTR, suggesting that TAR has no effect on IE1 transactivation of the HIV LTR. However, when TAR was used in association with an LTR containing mutations in both NF-KB sites, CAT expression was not activated at all by IE1 (Fig. 3, lanes 7 and 8) . These results confirm the central role of NF-KB in IE1 transactivation and further demonstrate that TAR is not involved.
EMSA using a probe containing the NF-KB sites of the HIV-1 LTR. Nuclear extracts were prepared from the human T lymphoid H9 and promonocytic U937 cell lines constitutively expressing IE1. As a negative control, nuclear extracts were also prepared from the same cell lines containing control expression vectors lacking the IE1 sequence. There was a very low basal level of the specific NF-xB band in the control cell lines (Fig. 4b,  lanes 1 and 5) , but IE1 expression greatly increased the amount of the DNA-protein complex (Fig. 4b, lanes 2  and 6) . This complex was specifically competed by an excess of unlabelled KB sequence, but not by a mutant oligonucleotide which was identical to the wild-type probe except for three point mutations (Fig. 4b, lanes 3,  4, 7 and 8) .
To confirm that this electrophoretically retarded DNA-protein complex was indeed NF-KB, nuclear extracts were pre-incubated with antibody specific for the p50 subunit of this transcription factor, before labelled probe was added. Pretreatment of nuclear extracts with antibody to p50 almost abolished the DNA-protein complex (Fig. 4 c, lanes 1 and 2) , whereas antibody specific for IE1 or pre-immune sera had no significant effect (lanes 1, 3 and 4) . This result indicated that the DNA protein complex activated by IE1 is indeed NF-KB. These data demonstrate that NF-xB is highly activated by the expression of IE1. Together with our mutation analysis, these results strongly suggest that the IE1 transactivation of the HIV-1 LTR occurs primarily by increasing NF-KB binding activity.
NF-KB is highly activated by IE1
It has previously been shown that IE1 itself is not a DNA-binding protein. This suggests that it activates the LTR indirectly through its effect on NF-KB (Cherrington & Mocarski, 1989; Sambucetti et al., 1989) . To test this hypothesis, we cotransfected cells with the IE1 expression vector and an NF-xB test plasmid containing a CAT gene fused to a promoter incorporating NF-KB-binding sites upstream from the TATA box of the c-fos gene (Pierce et al., 1988) . It has previously been shown that the activity of this promoter depends on the presence of NF-KB. As a negative control, the same plasmid containing point mutations in the NF-xB sites was used. Both plasmids were transfected into cells and CAT activity was determined to measure the induction of NFxB activity. With the mutant xB plasmids, very low levels of CAT activity were detected even with cotransfection of the IE1 expression vector (Fig. 4a, lanes 3 and 4) . However, when cells were transfected with the wild-type NF-KB plasmid, CAT activity was highly induced in the presence of IE1 (Fig. 4a, lanes 1 and 2) .
To confirm the above observation, we also performed
Roles of general transcriptional elements located downstream from NF-tcB sites
The above results clearly confirm an essential role for NF-KB in the upregulation of the HI¥ LTR by IE1. However, other published data, although often contradictory, have suggested that transcription elements such as TATA or its immediate upstream sequences could be involved (Biegalke & Geballe, 1991; Ghazal et al., 1991 ; Hagemeier et al., 1992; Walker et al., 1992) . To test the possible involvement of other sequences, we have generated a series of mutants which specifically lack one of the three major transcriptional elements of the LTR, NF-KB, Sp 1 and the TATA box. Plasmid p942 has point mutations in the KB sites as reported by Nabel & Baltimore (1987) , whereas the Spl sites or TATA box were selectively removed and replaced by restriction linkers in plasmids pASpl and pATATA, respectively. These mutant constructs were transfected into U937 cells, and transient expression of the CAT enzyme was used to measure the contribution of these elements to IE 1-driven transactivation of the HIV LTR. As expected, mutations of the KB sites significantly lowered CAT activity (Fig. 5, lanes 3 and 4) . Removal of the three Spl sites significantly lowered the ability of the LTR to respond to IE1, but residual amounts of CAT activity were reproducibly observed (Fig. 5 , lanes 5 and 6). Mutations in the T A T A box resulted in undetectable levels of CAT activity (Fig. 5, lanes 7 and 8) . This result indicated that general transcription elements such as the Spl sites and the TATA box are needed for IEl-driven transactivation of the LTR. This result was expected because the TATA box and Spl sites are required for the activation of the HIV LTR by many stimulators, including Tat, tumour necrosis factor alpha (TNF-~), E1A/E1B and phorbol myristate acetate (PMA) (Harrich et al., 1989 (Harrich et al., , 1990 Kliewer et al., 1989; Leonard et al., 1989; Perkins et al., 1993) .
Discussion
We have demonstrated that NF-~cB is essential for IE1-driven transactivation of the HIV LTR. First, we confirmed that the IE1 expression vector used in this study indeed produced IE1 by metabolic labelling and immunoprecipitation using antibody specific to the 72 kDa IE1 protein. Our combined mutation analysis indicated that changing the KB sites alone was sufficient to abrogate IE1 activation of the LTR, and that the TAR sequence has no rote in IE1 transactivation. The Spl sites and the TATA box are also needed for IEl-driven transactivation. However, their effects are probably indirect, as these are the elements involved in the general transcription machinery and are needed for basal level gene expression. Similarly, PMA and TNF-~ increase transcription from the LTR by activating NF-~cB, but this transcriptional activation still requires Spl and the TATA box (Harrich et al., 1990; Perkins et al., 1993) . This is also true for Tat transactivation of the L T R (Harrich et al., 1989) , as although TAR is the primary nucleotide sequence required, optimum Tat-driven transactivation of the L T R also needs Spl sites and the TATA box. Finally, we have demonstrated, by EMSA using nuclear extracts prepared from two human cell lines stably expressing the IE1 protein, that IE1 strongly induces NF-~cB activity. It is still not clear why there has been so much discrepancy between reports from different laboratories. We do not believe that the use of different cell lines is responsible, because we have obtained similar data using a number of different human cell lines, including H9 and HeLa. However, it is possible that the IE1 expression vectors used in other studies might have expressed less than optimum levels of IE1, because protein expression from vectors was not demonstrated in these reports. We also note that most mutations introduced into the HIV LTR were gross deletions rather than the removal of specific elements, which could also affect basal transcription.
It has been reported that HCMV can enter monocytes and T lymphocytes, and express ILl (Einhorn & Ost, 1984; Nowlin et al., 1991 ; Rice et al., 1984; Schrier et al., 1985) . In addition, HCMV is able to produce infectious virus at a very low level in peripheral blood monocytes (Maciejewski et al., 1993; Minton et al., 1994) . Although growth of HCMV is restricted in lymphocytes, ILl is expressed (Einhorn & Ost, 1984; Nowlin et al., 1991; Rice et al., 1984; Schrier et at., 1985) . These two cell types are the major target cells for HIV in the body, so it is clearly possible that ILl acts as a viral cofactor for HIV. There are many possible scenarios for the interactions between HIV and HCMV. For example, HIV might enter a T cell latently infected with HCMV, and HIV gene expression might proceed more rapidly as a result of ILl transactivation. Because the majority of people are already infected with HCMV, these are clearly possible pathways. Alternatively, as the immunity of individuals infected with HIV declines, HCMV may replicate more actively and may enter HIV-infected cells at higher frequency, which in turn may lead to increased HIV gene expression and accelerated progression to AIDS. Whatever the mechanism, it is clearly important to understand at the molecular level the interactions between ILl and the HIV LTR and between ILl and NF-~cB. This study has demonstrated these interactions and will also shed more light on the mechanism of the interaction between HCMV and its host cells.
